JP2023528454A - 線維芽細胞増殖因子受容体２に特異的に結合する二重パラトープアンタゴニスト抗体およびその使用方法 - Google Patents

線維芽細胞増殖因子受容体２に特異的に結合する二重パラトープアンタゴニスト抗体およびその使用方法 Download PDF

Info

Publication number
JP2023528454A
JP2023528454A JP2022574398A JP2022574398A JP2023528454A JP 2023528454 A JP2023528454 A JP 2023528454A JP 2022574398 A JP2022574398 A JP 2022574398A JP 2022574398 A JP2022574398 A JP 2022574398A JP 2023528454 A JP2023528454 A JP 2023528454A
Authority
JP
Japan
Prior art keywords
antibody
fgfr2
antigen
gal
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022574398A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023528454A5 (https=
Inventor
サイルーデ チャトゥランタブト
ウィリアム セラーズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Broad Institute Inc
Original Assignee
Broad Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Broad Institute Inc filed Critical Broad Institute Inc
Publication of JP2023528454A publication Critical patent/JP2023528454A/ja
Publication of JP2023528454A5 publication Critical patent/JP2023528454A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022574398A 2020-06-03 2021-06-02 線維芽細胞増殖因子受容体２に特異的に結合する二重パラトープアンタゴニスト抗体およびその使用方法 Pending JP2023528454A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063033975P 2020-06-03 2020-06-03
US63/033,975 2020-06-03
PCT/US2021/035468 WO2021247718A1 (en) 2020-06-03 2021-06-02 Antagonistic biparatopic antibodies that specifically bind fibroblast growth factor receptor 2 and methods of using same

Publications (2)

Publication Number Publication Date
JP2023528454A true JP2023528454A (ja) 2023-07-04
JP2023528454A5 JP2023528454A5 (https=) 2024-06-10

Family

ID=78829919

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022574398A Pending JP2023528454A (ja) 2020-06-03 2021-06-02 線維芽細胞増殖因子受容体２に特異的に結合する二重パラトープアンタゴニスト抗体およびその使用方法

Country Status (7)

Country Link
US (1) US20230295308A1 (https=)
EP (1) EP4161566A4 (https=)
JP (1) JP2023528454A (https=)
CN (1) CN116367855A (https=)
AU (1) AU2021284297A1 (https=)
CA (1) CA3185812A1 (https=)
WO (1) WO2021247718A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250148746A (ko) * 2023-01-13 2025-10-14 리제너론 파아마슈티컬스, 인크. Fgfr3 결합 분자 및 그의 사용 방법
CN118852431A (zh) * 2023-04-28 2024-10-29 武汉人福创新药物研发中心有限公司 抗FGFR2b单抗
WO2025070733A1 (en) * 2023-09-29 2025-04-03 Chugai Seiyaku Kabushiki Kaisha Anti-rtk antibodies and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015504434A (ja) * 2011-11-23 2015-02-12 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 抗ｆｇｆｒ２抗体およびその使用
JP2016518332A (ja) * 2013-03-13 2016-06-23 ノバルティス アーゲー 抗体薬物コンジュゲート
JP2017503480A (ja) * 2013-11-27 2017-02-02 ザイムワークス，インコーポレイテッド Ｈｅｒ２を標的とする二重特異性抗原結合性コンストラクト
JP2017538442A (ja) * 2014-11-05 2017-12-28 ジェネンテック， インコーポレイテッド 抗ｆｇｆｒ２／３抗体及びその使用方法
WO2018090052A1 (en) * 2016-11-14 2018-05-17 Amgen Inc. Bispecific or biparatopic antigen binding proteins and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2083081A1 (en) * 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with FGFR fusion proteins
HUE035700T2 (en) * 2008-11-07 2018-05-28 Galaxy Biotech Llc Monoclonal antibodies to Fibroblast Growth Factor receptor 2
CN107446045A (zh) * 2016-07-22 2017-12-08 北京天广实生物技术股份有限公司 一种抗her2的抗体、其药物组合物及用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015504434A (ja) * 2011-11-23 2015-02-12 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 抗ｆｇｆｒ２抗体およびその使用
JP2016518332A (ja) * 2013-03-13 2016-06-23 ノバルティス アーゲー 抗体薬物コンジュゲート
JP2017503480A (ja) * 2013-11-27 2017-02-02 ザイムワークス，インコーポレイテッド Ｈｅｒ２を標的とする二重特異性抗原結合性コンストラクト
JP2017538442A (ja) * 2014-11-05 2017-12-28 ジェネンテック， インコーポレイテッド 抗ｆｇｆｒ２／３抗体及びその使用方法
WO2018090052A1 (en) * 2016-11-14 2018-05-17 Amgen Inc. Bispecific or biparatopic antigen binding proteins and uses thereof

Also Published As

Publication number Publication date
EP4161566A1 (en) 2023-04-12
CA3185812A1 (en) 2021-12-09
US20230295308A1 (en) 2023-09-21
WO2021247718A1 (en) 2021-12-09
AU2021284297A1 (en) 2023-02-02
CN116367855A (zh) 2023-06-30
EP4161566A4 (en) 2024-06-12

Similar Documents

Publication Publication Date Title
JP6093692B2 (ja) 抗ｌｒｐ６抗体
AU2011293127B2 (en) Notum protein modulators and methods of use
US11434482B2 (en) Methods of identifying bacteria comprising binding polypeptides
CN119490599A (zh) 用于治疗癌症的dll3/cd3结合蛋白
CN103360496B (zh) 抗ephb4抗体及其使用方法
HK1212362A1 (en) Coiled coil and/or tether containing protein complexes and uses thereof
CN103193885B (zh) 抗ephrinb2抗体及其使用方法
JP2023528454A (ja) 線維芽細胞増殖因子受容体２に特異的に結合する二重パラトープアンタゴニスト抗体およびその使用方法
JP2021046417A (ja) 抗Ａｇｇｒｕｓモノクローナル抗体、ＣＬＥＣ−２との結合に必要なＡｇｇｒｕｓの領域、及びＡｇｇｒｕｓ−ＣＬＥＣ‐２結合阻害剤のスクリーニング方法
CN118647633A (zh) 抗独特型抗体分子及其用途
JP2024505674A (ja) 抗ｉｌ１ｒａｐ抗体
WO2020156507A1 (zh) 抗pd-l1的新型抗体及其用途
KR20240161970A (ko) 항-par2 항체
EP4506361A1 (en) Antibody against c-met and use thereof
WO2026052582A1 (en) Biparatopic antibodies that specifically bind fms related receptor tyrosine kinase 3
WO2024173565A2 (en) Human synthetic antibodies targeting human epidermal growth factor receptor 2 (her2) mutants
KR20250103815A (ko) 인테그린 알파11에 결합하는 항체 및 이의 용도
HK1251581B (en) Methods of identifying bacteria comprising binding polypeptides
HK1214277A1 (zh) 生产异源多聚体蛋白质
HK1175790A (en) Coiled coil and/or tether containing protein complexes and uses thereof
HK1178910A1 (en) Humanized anti cxcr4 antibodies for the treatment of cancer
HK1178910B (en) Humanized anti cxcr4 antibodies for the treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230203

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240531

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240531

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20251105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260422